Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy

CD22, a member of Siglec family of sialic acid binding proteins, has restricted expression on B cells. Antibody-based agents targeting CD22 or CD20 on B lymphoma and leukemia cells exhibit clinical efficacy for treating these malignancies, but also attack normal B cells leading to immune deficiency....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Angew Chem Int Ed Engl
Prif Awduron: Hong, Senlian, Yu, Chenhua, Wang, Peng, Shi, Yujie, Cao, Weiqian, Cheng, Bo, Chapla, Digantkumar G., Ma, Yuanhui, Li, Jie, Rodrigues, Emily, Narimatsu, Yoshiki, Yates, John R., Chen, Xing, Clausen, Henrik, Moremen, Kelly W., Macauley, Matthew Scott, Paulson, James C., Wu, Peng
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7980786/
https://ncbi.nlm.nih.gov/pubmed/33314603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.202005934
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg